Kanagaraj Rajalakshmi

Dr. Kanagaraj Rajalakshmi


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 June 2025 in Pathology - Research and Practice
Verified
Journal Article
Closed access
YCYumei Chen
Yumei Chen
DYDenghua Yu
Denghua Yu
DZDongwei Zhu
Dongwei Zhu
SMSelvaraj Muthusamy
Selvaraj Muthusamy
MDMangirish Deshpande
Mangirish Deshpande
CZChengdong Zhu
Chengdong Zhu

14 December 2024 in Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy
Verified
Journal Article
Closed access
DZDongwei Zhu
Dongwei Zhu
JDJindong Dai
Jindong Dai
JJJue Jia
Jue Jia
TKThangamani Kanagaraj
Thangamani Kanagaraj
KRKanagaraj Rajalakshmi
Kanagaraj Rajalakshmi
GYGuoyue Yuan
Guoyue Yuan

25 August 2024 in Journal of Molecular Liquids
Verified
Journal Article
Closed access
XLXiaojian Liu
Xiaojian Liu
JDJindong Dai
Jindong Dai
JSJian Shen
Jian Shen
DZDongwei Zhu
Dongwei Zhu
KRKanagaraj Rajalakshmi
Kanagaraj Rajalakshmi
KPKannan Palanisamy
Kannan Palanisamy

5 October 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
YDYan Dong
Yan Dong
XXXifang Xu
Xifang Xu
SSSathyamoorthi S
Sathyamoorthi S
JDJindong Dai
Jindong Dai
VMVijayakumar Murugesan
Vijayakumar Murugesan
DZDongwei Zhu
Dongwei Zhu
Rheumatoid arthritis (RA) is a persistent autoimmune condition that predominantly affects the joints resulting in inflammation, pain and progressive disability. Immunological imbalance, especially the stimulation of pathogenic immune cells, including T and B cells, macrophages, amongst others, is the cause of the disease, as it is critical to the development of the disease. The limitation of traditional anti-RA medications, such as non-steroidal anti-inflammatory drugs (NSAIDs) and disease-modifying anti-rheumatic drugs (DMARDs), in the treatment of the disease led to the development of more specific medicines. One of the most promising biologic agents, including monoclonal antibodies, cytokine inhibitors and cell-based therapies, are specifically targeting immune cells and inflammatory pathways in RA. This review examines these new immunotherapies, their mechanisms of action, clinical efficacy, and challenges associated with them, including resistance to treatment, safety issues, and the necessity to use personalised therapy. Also, the new immunotherapeutic approaches, which include targeting autoantibodies, gene therapy, and precision medicine, are promising new approaches that could result in more effective and personalised treatments. Finally, the review concludes with a discussion of future directions, where in combination therapies, next-generation biologics, and personalised treatment regimens are also possible and can change the way RA can be managed in the future. To preserve analytical depth, this review explicitly distinguishes established (regulatory-approved) therapies from investigational and experimental approaches and indicates the level of clinical evidence for each.